A biotechnology company with cell biology and genetic engineering platform was developing a new generation of engineered cell therapies. Their core therapeutic areas include neurology, cardiology, and immunology.
They were seeking to pursue clinical development and commercialization of key program and pursue partnering opportunities and out-licensing options. They desired a prioritized partner list and development of “pitch deck” to highlight program value proposition and to engage potential partners.
- Assess technology platform and ID complementary autoimmune and inflammatory disease indications
- Evaluate, rank and prioritize indications based on scientific, clinical/regulatory and payer/market criteria
- Detailed assessments on prioritized indications and final indication rankings and development of TPPs